Welcome to the QIAGEN NV investor and analyst conference call on the Q3 results 2012. (Operator Instructions) I would now like to turn the conference to John Gilardi, VP Corporate Communications. Please go ahead.

Good afternoon and welcome to our conference call to discuss our latest quarterly results. Joining me on the call are Peer Schatz, our Chief Executive Officer, and Roland Sackers, our Chief Financial Officer. A copy of the announcement and the presentation can be downloaded from the Investor Relations section of our home page at qiagen.com. Before we begin, I’d like to thank you for your understanding on our decision to postpone the announcement for a few days. We always strive for equal access to information about QIAGEN and that investors have access to both NASDAQ, where about half of our daily trading takes place, and the Frankfurt Stock Exchange. So given the weather in the U.S. last week and also the fact that we had a holiday in Europe, we thought this was the best option. And for those of you in the U.S. and the areas hit by the storm, we hope that you and your families are in good shape and came through this situation as good as possible. Before I turn over to Peer, please keep in mind that the following discussion and response to your questions, reflect the views of management as of today, November 5, 2012. Today we will be making statements and providing responses to your questions that include our intentions, beliefs, expectations, or predictions of the future. These constitute forward-looking statements for the purpose of the Safe Harbor provisions. They involve certain risks and uncertainties that could cause our actual results to differ materially from those projected. QIAGEN disclaims any intention or obligation to revise any forward-looking statements. For more information, please refer to our filings with the U.S. Securities and Exchange Commission, which you can also find our website. I’d like to now hand over to Peer.

Yeah. Thank you, John. Hello. I would like to welcome you to our conference call and the opportunity to discuss our results for the third quarter and first nine months of 2012. As you saw in our release last night, we are achieving our goal to deliver faster growth in 2012 despite the challenging macro business environment. We are pleased with our progress and we delivered on the targets set for the third quarter. Our focus on driving innovation and growth is paying off. Based on the good performance so far in 2012, we have reaffirmed our full year outlook. In the third quarter, net sales rose 10% at constant exchange rates and were up 5% on a reported basis to $304 million on growth across all customer classes and regions. Adjusted operating income grew 12% to $84 million, and adjusted diluted EPS rose to $0.26 per share, which was $0.01 ahead of our target. As you can see on this slide, we had similar growth rates for the first nine months of the year. Net sales were up 12% to $908 million, and adjusted EPS rose to $0.74 per share. These results give us confidence about our full-year targets. At the start of 2012, we took a balanced view on a range of opportunities and risks. These included contributions from the recent acquisitions and expectations for growth in all customer classes and regions. We also took into consideration the challenging environment, especially in the U.S. and Europe. As you can see, these factors have so far been largely playing out as we had anticipated. In terms of the 10% constant exchange rate growth in the third quarter, about seven percentage points came from the acquisitions of Cellestis, Ipsogen, and AmniSure. The rest of our business added about three percentage…

Yes. Thank you, Peer, and good afternoon to everyone in Europe and good morning to those joining from the U.S. As you heard from Peer, for the third quarter of 2012, we achieved our target for net sales and exceeded it for adjusted EPS, having made significant progress on our strategic initiatives. We are committed to actualizing full-year growth in 2012 over 2011. And based on the ongoing strong performance for the first nine months of 2012, we are reaffirming our full-year outlook for higher net sales and adjusted EPS. Before I go into more detail on the outlook, I will briefly review the results. On Slide 6, you see our key results for the third quarter. Net sales growth was a mix of benefits from the acquisitions of Cellestis, Ipsogen, and AmniSure as well as expansion as a result of the business amidst the challenging market conditions. Adjusted gross profit was 6%, or approximately $290 million. The adjusted gross profit margin remained steady at 72% compared to the third quarter of 2011, but was slightly higher than in the second quarter of 2012. With three consecutive quarters above 70%, we are confident of achieving our full-year target for an adjusted gross margin of about 71%. I want to highlight here that we have been able to maintain this level through various initiatives, especially since the QuantiFERON latent TB test, which is manufactured by a third party, has a gross margin below the average for consumables. Adjusted operating income rose 12% to $84 million over the third quarter of 2011, and the adjusted operating margin improved to 28% of net sales from 26% a year ago. We have been restructuring our organization as part of the efficiency initiative launched in late 2011, and we expect more benefits to come. Adjusted…

Thank you, Roland. I’m now on Slide 11 to quickly review the achievements of 2012 and the progress we are making on our strategic initiatives. In addition to the QIAsymphony roll-out, we are moving ahead with our next generation sequencing initiative. In many ways, we are repeating a strategy that has worked out very well for us, developing customer-friendly, automated work flows involving breakthrough technologies. We did this with real-time PCR, and you can see the success with QIAsymphony RGQ. With the addition of the QIAGEN next generation sequencing portfolio, we will have a very strong competitive position to offer customers a broad range of technologies with complete proven routine work flows. In terms of adding content, a number of projects are moving ahead towards key submissions by the end of the year. This includes a TheraScreen EGFR test in the United States as a companion diagnostic for use in lung cancer patients. In combination with a recent approval for the KRAS test, gaining approval for the EGFR test in the United States will complement the existing approvals in Japan, Europe, and other important markets around the world. After our direct entry into India and Taiwan during 2011, we are reviewing options to further expand into new markets. The top seven markets are growing at a very attractive pace, up 24% on a constant exchange rate basis in the first nine months of the year, and providing 11% of sales. The efficiency program launched in late 2011, along with a series of organizational leadership changes, are having a positive impact on QIAGEN. These actions will help improve our growth and profitability in 2013 and beyond. I’m now on Slide 12. We’ve been talking about the various growth drivers in molecular diagnostics, and it is important to consider what they are…

Yeah. Thank you, Peer. I’m now on Slide 18 to review some of the details about our share repurchase program and the recent U.S. private placement. As for the share repurchase, this is a signal of our commitment to improving returns to shareholders and also that we feel our shares are significantly under-valued. We have begun the repurchase of up to $100 million of our shares, which represents about six million shares based on current stock price. The program was launched on October 1, and so far, we have bought back about half a million shares for about $10 million on the Frankfurt Stock Exchange. Also in the release and in line with the comments we made on the second quarter conference call, we took advantage of the currently low interest rate environment and completed our first debt raising activity in the U.S. The $400 million of long-term debt came from U.S. insurance companies in the form of a private placement. A voucher was held during the third quarter and the pay-out was in mid-October. You can see that’s offering attractive, strong demand and we succeeded in getting a very attractive yield. We see the higher interest rate expenses from raising this debt as a worthwhile short-term tradeoff, given the risk for higher interest rates in the future. As for the net impact of these activities, we see it as about $0.005 of dilution on adjusted EPS for the fourth quarter, but we can’t observe this with our existing outlook. As a preliminary estimate for 2013 – and this is all subject to the speed at which we complete the share repurchase program – we currently expect a net impact of about $0.01 of dilutions for the full year. This estimate is based on higher after-tax net interest expense of…

Yeah. Thank you, Roland. I’m now on Slide 20 for the summary before we move into Q&A. We’re performing well in a challenging macroeconomic environment in 2012, achieving our goals for innovation and growth. Let me review again what we have announced. We achieved our targets for the third quarter of 2012 in terms of net sales and adjusted EPS growth. Based on the performance so far in 2012, we have reaffirmed our full-year targets, despite the challenging business environment. We are actively developing our company while enhancing shareholder value, and at the same time, maintaining our financial strength and flexibility. Our program to repurchase up to $100 million of shares is underway. This is a signal of our conviction in our future prospects and views that there is significant value potential in our shares. At the same time, we have strengthened our balance sheet through our first U.S. debt offering at very attractive rates. This will provide longer term financial capabilities to support our business expansion. In closing, we remain on track in 2012 and are optimistic about achieving our targets and delivering a stronger performance in 2012. And with that, I’d like to hand back to the operator to open the Q&A session. Thank you.

Thank you. Ladies and gentlemen, at this time we will begin the question-and-answer session. (Operator Instructions) And the first question comes from Romain Zana from Exane BMP Paribas. Please go ahead. Romain Zana – Exane BNP Paribas: Yes. Good afternoon, gentlemen. I have three questions, actually. The first one, I think, Peer, you mentioned that the 4% to 5% organic growth guided for the full year is still confirmed. So I was wondering what makes you confident that you can achieve such significant acceleration, especially given the very tough comps. The second question will be on the margin improvements, because you previously mentioned that the guided margin improvement for 2013 especially will be mainly driven by SG&A cost management. And it seems that so far, it has come from lower R&D costs. So first I was wondering is that sustainable. And second, do you expect optimization of SG&A? When do you expect SG&A optimization to deliver? And last question just on profiling, if you could give us more color on the constant exchange rate growth that you achieved in Q3. Thank you.

Okay, great. Thanks, Romain. Good questions. I’ll take one and three, and Roland, if you could then take two. So I’ll start out with the last question. Profiling is delivering very nicely, and the growth is definitely driven by the QIAsymphony placements. The overall franchise is developing very nicely. The revenues are not a good indication of that good growth, because we’re clearly seeing a lot of reagent rental placements. QIAsymphony, the platform that is driving this growth, is typically being placed now under reagent rentals. The majority of these placements are in the clinical lab. The majority of these placements are actually in combination with some sort of a tail to it in terms of reagent streams or similar. So with this, we are definitely seeing an impact on the top line in terms of these instruments not being recognized anymore as straight cash sales. But they are now being structured on these lease agreements. If you factor this out, you actually get to very good growth rates in this area as well. And we expect this to continue over the foreseeable future as this system is developing very nicely. In Europe, we’re primarily placing with a complete menu of approved tests. In the U.S., it’s primarily for LDTs. And now with the emerging visibility of the menu coming onto the system, they will be added to that growth and drive that further. We’re actually seeing very strong uptake also in the U.S. of the system, and it’s a very balanced placement profile. So number two is – Romain, I hope you understand I won’t give the details on this subgroup. I can only confirm that this is an area that we continue to see and expect to see good growth in. Romain Zana – Exane BNP Paribas: Yeah. I see.

And the 4% to 5% growth rate for the year, this is something that we’re pretty much there in the third quarter. We were a little bit above that in the first half of the year. There are always special programs, deals, tenders, initiatives, new product roll-outs and these types of things that drive these types of forecasts. And this was carefully done, and as Roland said, we think we can even be in the mid- to high end of the range of the forecast for the fourth quarter of 2012. So there’s not a specific factor I would point to. Again, there is caution around will Sandy have continued impact. We don’t necessarily factor in a big number yet beyond what we’ve seen today. And the elections are always a question mark. But we feel very comfortable in giving this guidance. Romain Zana – Exane BNP Paribas: Does it mean that order book actually gives you visibility on this?

It’s typically the pipeline. If you remember, a lot of our products are purchased and delivered overnight or within a very few days. So it’s basically the pipeline, the leads that we see and also the customer feedback that has been given to us in terms of demand now over the next few weeks. Romain Zana – Exane BNP Paribas: Okay.

And in terms of margin development, Romain, a couple of reasons as you know, in terms of pricing, QIAGEN typically is able to increase prices ex-HPV. I do believe even in a more challenging environment, right now we will see some improvements here. The second reason is clearly in terms of utilization of our production environment. I do believe that there is still room for flexibility for QIAGEN, but still I know our utilization ratio somewhere around 50% to 65%. So more volume, same kind of equipment gives us a clearly better costing situation. In terms of R&D, you shouldn’t forget that, of course, especially over the last 18 months, we have seen a significant number of deals with the Pharma companies around companion diagnostics. So, have in mind that even if you see a certain volatility around R&D expenses, that doesn’t mean that actually our R&D firepower decreased. It actually means that the firepower significantly has increased without hitting our P&L too much. In terms of leveraging SG&A, I think it’s also important to know that you have to look at it on a yearly number and typically, the fourth quarter is also here our best quarter. And looking in 2013, we’re clearly sticking to our EBIT operating income margin goals, as indicated in our long-term plan. Romain Zana – Exane BNP Paribas: Okay. Will it be fair to say that -

Romain, I’m sorry. We need to move on. We have a queue of other people. So operator, if we can move on, please. And let’s try to keep it to one question to give everybody a chance.

The next question today comes from Tycho Peterson from JP Morgan. Tycho Peterson – JP Morgan: Hey, thanks for taking the question. As we think about the early traction with the KRAS assay post-FDA approval, can you just talk about reception in the market, how you think about that tracking? And I guess just more broadly on companion diagnostics, do you see any risk around sample access for some of these programs, given that most of the samples for development have to come out of Pharma?

Good. Good questions. I would like to start with the second first. Our business model is that we partner with Pharma, and by doing that, we ensure a perfect clinical profile, or as perfect as it gets clinical profile, because we actually work with them on their samples that they are actually using in their own clinical trials where their drug is being validated as well. So our business model actually takes very differently to most other players in this space, the diagnostic into complete alignment with the drug. And therefore, the sample access is part of that benefit that we have, one of the many benefits. It is often a more onerous road, but one that we think is the right one to take. In terms of the uptake, we’ve seen very good receptivity in the U.S. on this. We have a very strong share in KRAS. We’re very often converting from the LDTs or RUO versions that have been used in the market previously. The conversion from Sanger sequencing is one that benefits – due to the specification benefits I gave you as part of the presentation. We’ve seen very good reception and we expect reimbursement and also regulatory changes to further amplify that over 2013. So we’re well on track and we had very high targets for conversion and we’re very confident that we can get them. Tycho Peterson – JP Morgan: Okay. I’ll hop back in the queue. Thanks.

Thanks.

The next question comes from Daniel Wendorff from Commerzbank. Daniel Wendorff – Commerzbank: Yes. Hi. It’s Daniel Wendorff from Commerzbank. Thanks for taking my question.

Hi, Daniel. Daniel Wendorff – Commerzbank: Hi. It’s related to the weakness in Pharma growth in Q3. Can you potentially already comment on whether you see this as an ongoing trend in light of the restructuring activities which will likely continue as well, and also which role does an increased use of Pharma companies, also of these reagent rental contracts, for instruments played in Q3? And maybe a little housekeeping item at the end, the $100 million share repurchase program, do you still intend to finish that in 2012? Thank you.

Okay. I’ll take the first and to Roland, if you could take the second. So Pharma, the trend on the development side continues to remain very strong. So the use of molecular tools in clinical development is definitely seeing a very strong demand. And that will continue for a very long time. Remember five, six, seven years ago, 50% or 60% of our sales, probably even more, were in the area of clinical – in the research area, the R part of R&D. And now we’re growing in D, and R is typically being seen under pressure and restructured. So the R part is not as much taken up in the biotech and other smaller industries. The D part is the one that continues to develop very nicely. It’s sometimes difficult to keep them apart. The QIAsymphony systems, or the reagent rentals, there are very few actually going into Pharma. The majority – and I’ve seen a lot of notes with other information – but actually, by far, the majority are in the clinical area and the diagnostic area. And the Pharma industry is a much smaller percentage of these placements. They’re starting to see the adoption, but they’re typically cash sales. So it wouldn’t have an impact. Roland?

Yeah. On the share buyback, we clearly are going to keep up our flexibility on the one hand side. On the other hand, we all know that especially in Europe we have a significant number of regulations around volume and so on, what you can do in a share buyback. So having that in mind, I do believe we are going to continue the share buyback in a similar pace as we have done it. But again, it’s also a question on total market volume and trading volume, and but all in, I wouldn’t believe that we are able to fulfill it in 2012. Daniel Wendorff – Commerzbank: Okay. Thank you very much.

Your next question comes from Brian Weinstein from William Blair. Please go ahead. Brian Weinstein – William Blair: Hi. Thanks for taking the question.

Hey, Brian. Brian Weinstein – William Blair: My question is on sequencing and what role FDA is going to need to play to get this done for you guys. I think per the AMP analyst that you were just talking about, kind of a mid-2013 type of a launch. So can you characterize your discussions with the agency and what they’re specifically looking for on the sequencing side? Thanks.

Yeah. Good questions, Brian. I think if somebody knew where this were going, then this would be helpful to everybody. And right now, there are definitely a lot of moving parts. If you look at the current regulatory pathways that next generation sequencing systems are going, they’re typically going for assays that probably never would be used in the format that they are being submitted for. Or it is for instrument-only submissions. Both really is not very helpful in the long-run and especially in an area where you see dramatically changing technologies and new improvements emerging almost on a quarterly, or certainly annual, basis. So I think the regulatory agency’s very open to, and very interested in, finding a way to find some sort of regulation around this. But to me the question is not necessarily the analytical or technical capability to do it; it’s the clinical validation. To really validate a high-end or a high-value clinical diagnostic test, it would need some quite significant validation. And that is still something very tricky, because more information makes it ever more complex and evermore difficult. So we see a strong role in the CLIA environment in U.S. We see a strong role for, perhaps, in the secondary or third line testing. We see a different situation in Europe and in Asia, with a more faster adoption, certainly in certain areas. But we’re pretty much agnostic. We have all our chips placed, we have great solutions for all segments, and we will just be able to offer, I think, a best-in-class solution for any type of shade that the customer wants. We’re prepared for all options. Brian Weinstein – William Blair: Okay. And a follow-up here would be when you look at your KRAS launch, can you talk about the economics of the test for you versus how it was being sold previously as kind of an LDT or in an RUO format, what the up-charge is for you guys. Thank you.

The economics are more favorable in a FDA-approved product compared to selling an RUO and LDT. It’s just much easier to sell. You can share the specifications, the performance benefits of the complete solution. It is much preferred by the salespeople, and that’s something that also reflects in the accelerated adoption. So the economics – it has been fully expensed, the R&D expenditure, around this. And so if the price is higher, it’s about a 30% to 40% higher price. We are obviously also showing a higher gross margin. Brian Weinstein – William Blair: So a 30% to 40% higher price?

Well, yeah. Typically RUOs in this range would be in the high-double-digit, $100 to $150 range, and so here we have a solid about $200 per test on price. And this is an approximation, but, yeah, it’s about that. Brian Weinstein – William Blair: Okay, great. Thank you very much.

Your next question comes from Bill Quirk from Piper Jaffray. Please go ahead. Bill Quirk – Piper Jaffray: Great. Thanks. Good afternoon, everybody. Say, just a follow-up on Brian’s question, Peer, with the higher priced approved assay for TheraScreen KRAS, can you talk a little bit about from the labs’ perspective? My understanding is that the reimbursement, the payers don’t really discriminate between an LDT and between an approved test, and so can you help us think a little bit about why the labs should adopt, when obviously the ASP to them is going to be a little higher? And then, secondly, just asking a question about long-term plans for QuantiFERON, can you just remind us at what point you might be able to bring the manufacturing in-house and then obviously capture that incremental margin? Thank you.

Sure. You’re right that in these early days, the differentiated reimbursement of an LDT versus an FDA-approved product is not there, but it has started. And we’ve already seen the first examples. There is one first mutation test that has received a differentiated reimbursement by a major payer. And we will continue to see that going forward, because it’s the right thing to do. And we are seeing that that is probably much more effective than the regulatory risk going forward. So I wouldn’t be surprised to see a more broader differentiation going forward. And this would be an amazing tilting situation. But we’re, right now, still in these early days, and there is this discussion out there, if it might change or not. And the first indications are that it is moving in that direction, but that remains to be seen. In terms of the QuantiFERON manufacturing, Roland, do you want to take that one?

Yeah. Right now we are working on that move. Right now the actual planning is sometime end of next year. We are clearly working to get it done earlier, but I wouldn’t expect it too much earlier next year. Bill Quirk – Piper Jaffray: Understood. Thanks a lot, guys.

The next question comes from Zarak Khurshid from Wedbush Securities. Zarak Khurshid – Wedbush Securities: Hi, guys. Thanks for taking the questions, a couple of just straightforward ones here from me, as it looks like KRAS is gaining some mind share here. So, where are we with the total penetration of the KRAS opportunity today? What is the size of that market? And if you could kind of break out U.S. versus Europe, that’d be great. And then, secondly, just on the sequencing strategy, upon launch, do you anticipate having a cost-per-base advantage versus some of the competitors? Thank you.

You know on the second question, if that’s okay, I would like to leave that for when we actually come out with the specifications of the system. I think there’s a lot to be told when we come out with these specifications, and I would like to leave it until then. We have shared some specifications, but I think that should remain the story for now. The KRAS adoption, we had a slide actually in the second quarter conference call that I could refer to. If you look at the number of tests that are being done currently in the United States, it’s somewhere in the range of 100,000 to 150,000, in theory, a potential opportunity that we’re penetrating into. And this is only for colorectal cancer, and as we disclosed, also in other press releases we have with other Pharma companies, also partnerships in other oncology areas where KRAS is one of the elements of the mix, or the test as well. So if you sum up everything, this is a significant high double-digit million dollar market opportunity if you cover several indications in a global geography. And that’s what you’ll see in companion, you’ll see a lot of $50 million to $120 million global market opportunities that in sum add up very nicely and have typically high margins. Zarak Khurshid – Wedbush Securities: Great. Thank you.

Thanks.

The next question comes from Vamil Divan from Credit Suisse. Vamil Divan – Credit Suisse: Yeah. Thanks for taking the question. I guess one is I just wanted to ask in terms of QIAsymphony, it sounds like you’re really pleased with the roll-out. Can you give any sense of how much uptake you had in the U.S. versus outside the U.S.?

Yeah. Well it has actually seen a very strong reception in the U.S., and the area it’s placed in is typically in the LDT and the broad menu LDT area at the moment. In Perception, you also will see the first assays coming through more on the esoteric side on us in our portfolio, and then a few of the larger ones in addition to the companion. So this is an area where we definitely have a sweet spot, a broad menu, a broad array of different samples, very difficult to process moving into standardized downstream format. So I’ve seen a few interviews out there asking questions is this something you would see in a typical Chlamydia lab or is this something you’d see in a typical HIV lab, or if this is something you’d see in a typical Cystic Fibrosis testing lab? And the answer is clearly no. It is typically the Esoteric lab where you’d see these placements being done. And this is, by the way, if you look at the labs, one of the faster growing areas of their business. So the U.S. has been a large part of the – in some court, has just been above the European area based on the large size of the LDT market in the U.S. And it’s very balanced compared to the overall revenue portfolio that we have. Vamil Divan – Credit Suisse: Okay. Thanks. I guess one other one if I could just squeeze in, in terms of the Applied Testing, where you guys did better than we were expecting this quarter. It looks like that’s doing well. Just ahead in terms of things to think about for the fourth quarter or looking into next year, kind of how you see that playing out, I know there’s a couple specifically you’ve mentioned about this quarter, which we’ve modeled going forward.

It’s a good question. We actually had a slide in on applied testing, but we had to take it out, because we were just pushing the time limit of our presentation a little bit, and we’ll do that in an upcoming call as well. The growth is primarily in the area of veterinary testing and forensic testing. In both areas, we have significantly expanded the assay menu in 2011 and are rolling those out in 2012. And this is delivering very strong organic growth in those areas. We also entered into food testing, but that’s much smaller. And the big drivers are currently the veterinary, forensics, to a certain amount, also Pharma, quality control and environmental, and then food testing. So this is about the ranking. Vamil Divan – Credit Suisse: Okay. Thank you.

Thank you.

The next question comes from Mr. Peter Welford from Jefferies.

Hi, Peter. Good morning. Peter Welford – Jefferies: Hi. Good morning. Thanks. I’ve just got, I think, two very boring questions left on the financials, which is with regards to the amortization of intellectual property and also the restructuring charges, both of those, both the amortization and the charges, seemed to tick-up markedly in the fourth quarter, looking at your 2012 outlook. Could you just give us some insight into that, particularly I guess the amortization and why that’s going to tick up in 4Q? Thanks.

Amortization, I actually think it’s not a significant change. But in terms of business integration, you are right. It’s roughly $15 to $20 million higher than we had said on the second quarter conference call. And that’s driven, as I said before, that we’re actually faster in speed and probably also getting closer to the finalization of our restructuring efforts. So, we clearly had a significant benefit here, as certain of our programs did quite well. By the way, this – the increase is all non-cash charges, so I don’t think that has any impact to our cash flow. We do expect also for the fourth quarter a significant increase in terms of cash flow generation. So it really has to do with if we are able to finally – faster work in our restructuring program efforts. Peter Welford – Jefferies: That’s great. Thanks.

The next question is from Jon Groberg from Macquarie. Jon Groberg – Macquarie: Thanks. Just one quick question from me, Peer, can you – I may have just missed the detail, but if you look at the molecular diagnostic business, it looks like all their growth came from acquisitions, and I think HPV was actually up 7%. So can you maybe just talk about what happened in those other businesses that were down? Just trying to understand that. Thanks.

Jon, they were not down. I’d be happy to share these – or discuss these numbers with you as you’d calculate them. But we have seen, actually, the growth across all these areas. In the profiling area, what particularly impacted the revenue growth and dampened it, was the fact that we are aggressively doing reagent rentals right now. Customers are pulling in a lot of reagent rental contracts, and that is reducing our instrumentation sales component, which was higher in 2011 and now much lower in 2012. And if you look at the Diagnostics segment, that is a higher portion of sales. Normally we have like 12% of our sales is actually higher in diagnostics, and if you basically have that, you see that there’s a significant slice taken out of the instrumentation component, which would take you up into very good growth rates, again, even on the calculation that you just gave. So this is where the big difference to 2011 is. So, if you look at our growth rates that we’re having right now, we’re actually seeing – and you factor those impacts back in, it’s actually a quite good growth rate that we’re seeing all across the diagnostics franchise, even across the company. Jon Groberg – Macquarie: Just to be clear, though, all the acquisitions, I think, fall under molecular diagnostics, right? That you’ve done this – the Ipsogen and the Cellestis and the AmniSure?

They fall to by far the largest percentage into that bucket, yeah. Jon Groberg – Macquarie: Okay. And so, what you’re saying is – was it maybe on instruments? So maybe whereas you had more instrument sales a year ago, that’s moved a lot more towards reagent rental. So the actual utilization of the test and other things you’re talking about are still growing, and you’re saying it was that delta there that caused maybe the overall ex-acquisitions, ex-currency to not be looking as though it’s growing as quickly.

Well, again, look – if you basically run a calculation, say last year you had 20% sales in instrumentation, and this year this falls down to 5% or so, you have about 15 percentage points of growth that you had to make up in different areas. Now this is not that you lose these sales. These are instruments that are placed out there against more than that in reagent commitments going forward in a very profitable reagent stream. So this is what we’re doing, actually moving away from straight sales that we had a lot of last year, and now moving much more aggressively in reagent rentals, as the customer validation period has kind of like taken its time. And in 2012, they’re moving into routine adoption. Jon Groberg – Macquarie: Okay. That’s a helpful clarification. Thanks.

Thanks, Jon.

The last question today comes from Mr. Jeff Elliott from Robert W. Baird. Please go ahead with your question. Jeff Elliott – Robert W. Baird: Yeah. Thanks for sneaking me in, guys. Just congrats on the private placement. I’m curious, given that you have placed that money, can you give us an update on your capital deployment and priorities for 2012 and then maybe 2013?

Thanks, Jeff. Roland, do you want to give a outline on that?

Yeah, sure. And thanks for the question. Yeah, I said before we are just started for the first time with the share repurchase program, and we still have a long way to go here. We just bought back roughly 10% of the authorized program. And I would say once we have finalized that, we – we’re looking for the next step. Right now, we clearly do believe our shares undervalued. We still have a very strong cash flow generation so we do believe in terms of capital and flexibility, we have a very good position right now. So I would say that gives us additional flexibility in doing the next step. Jeff Elliott – Robert W: Baird. Thank you.

So, with that, I’d like to close the conference call and thank all of you for participating. And if you have any additional questions, don’t hesitate to give us a call or send a note and we’ll get back to you. With that, thank you very much.

Thanks.

Ladies and gentlemen, this concludes the Q3 Investor and Analyst Conference Call of QIAGEN NV. Thank you for participating. You may now disconnect.